Pfizer-BioNTech vaccine candidate induces immune response in early-phase clinical trial: Study
Posted by
www.biotecnika.org
According to the study the vaccine candidate is delivered
intramuscularly, and enables human cells to produce proteins part of
the SARS-CoV-2 receptor-binding domain, against which the immune
system is trained to produce antibodies.
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/pfizer-biontech-vaccine-candidate-induces-immune-response-in-early-phase-clinical-trial-study/articleshow/77504346.cms
Subscribe to:
Post Comments (Atom)
Post a Comment